glp-1 receptor agonist manufacturers must adapt to growing and GIP/GLP-1 agonists markets Frontiers | GLP-1 receptor agonist

GLP-1, GIP/GLP-1, and GCGR/GLP-1 Receptor Agonists: Novel Therapeutic Agents for Metabolic Dysfunction-Associated Steatohepatitis

Although it shared similarities with weight management trials in design and dosing, BP reductions were more modest (3.3 mm Hg SBP, 0.6 mm Hg DBP), likely reflecting the high baseline cardiovascular risk and widespread use of antihypertensive drugs in the study population

Front Aging Neurosci

DPP-4 inhibitors are body weight neutral and they are generally tolerated well without side effects (see also corresponding section below) (12, 19, 21, 22)

Patients with diabetes already face elevated pancreatitis risk due to obesity, hypertriglyceridemia, and metabolic syndromeconditions common among those prescribed GLP-1 medications

Serious complications like pancreatitis or gallbladder issues are rare but should prompt immediate consultation with a healthcare professional